Literature DB >> 34275860

Immunoinformatics approaches to explore B and T cell epitope-based vaccine designing for SARS-CoV-2 Virus.

Zohaib Bashir1, Syed Umair Ahmad1, Bushra Hafeez Kiani2, Zainab Jan1, Nayab Khan3, Umama Khan4, Ihteshamul Haq5, Fazli Zahir6, Amara Qadus7, Tariq Mahmood1.   

Abstract

SARS-CoV-2, a new world coronavirus belonging to class Nidovirales of Coronaviridae family causes COVID-19 infection which is the leading cause of death worldwide. Currently there are no approved drugs and vaccines available for the prevention of COVID-19 infection, although couples of immunizations are being tested in clinical trials. However, the present efforts are focused on computational vaccination technique for evaluating candidates to design multi-epitope-based vaccine against pathogenic mechanism of novel SARS-COV-2. Based on recent published evidence, we recognized spike glycoprotein and envelope small membrane protein are the potential targets to combat the pathogenic mechanism of SARS-CoV-2. Similarly, in the present study we identified epitope of both B and T cell associated with these proteins. Extremely antigenic, conserve, immunogenic and nontoxic epitope of B and T cell of Spike protein are WPWYVWLGFI, SRVKNLNSSEGVPDLLV whereas the CWCARPTCIK and YCCNIVNVSL are associated with envelope small membrane protein were selected as potential candidate for vaccine designing. These epitopes show virtuous interaction with HLAA0201 during molecular docking analysis. Under simulation protocol the predicted vaccine candidates show stability. Collectively, this work provides novel potential candidates for epitope-based vaccine designing against COVID-19 infection.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34275860

Source DB:  PubMed          Journal:  Pak J Pharm Sci        ISSN: 1011-601X            Impact factor:   0.684


  1 in total

1.  EpiCurator: an immunoinformatic workflow to predict and prioritize SARS-CoV-2 epitopes.

Authors:  Cristina S Ferreira; Yasmmin C Martins; Rangel Celso Souza; Ana Tereza R Vasconcelos
Journal:  PeerJ       Date:  2021-11-30       Impact factor: 2.984

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.